176 related articles for article (PubMed ID: 21442354)
1. Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice.
Attems J; Ittner A; Jellinger K; Nitsch RM; Maj M; Wagner L; Götz J; Heikenwalder M
J Neural Transm (Vienna); 2011 May; 118(5):737-45. PubMed ID: 21442354
[TBL] [Abstract][Full Text] [Related]
2. Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease.
Attems J; Preusser M; Grosinger-Quass M; Wagner L; Lintner F; Jellinger K
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):23-32. PubMed ID: 17961140
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
Köhler C; Bista P; Götz J; Schröder H
Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
[TBL] [Abstract][Full Text] [Related]
4. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L.
Sasaki A; Kawarabayashi T; Murakami T; Matsubara E; Ikeda M; Hagiwara H; Westaway D; George-Hyslop PS; Shoji M; Nakazato Y
Brain Res; 2008 Jun; 1214():159-68. PubMed ID: 18457819
[TBL] [Abstract][Full Text] [Related]
5. Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.
Onishi T; Matsumoto Y; Hattori M; Obayashi Y; Nakamura K; Yano T; Horiguchi T; Iwashita H
Neurosci Res; 2014 Mar; 80():76-85. PubMed ID: 24406748
[TBL] [Abstract][Full Text] [Related]
6. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
Kulic L; Wollmer MA; Rhein V; Pagani L; Kuehnle K; Cattepoel S; Tracy J; Eckert A; Nitsch RM
Neurobiol Aging; 2011 Oct; 32(10):1827-38. PubMed ID: 19942317
[TBL] [Abstract][Full Text] [Related]
7. Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice.
Hosokawa M; Arai T; Masuda-Suzukake M; Kondo H; Matsuwaki T; Nishihara M; Hasegawa M; Akiyama H
J Neuropathol Exp Neurol; 2015 Feb; 74(2):158-65. PubMed ID: 25575133
[TBL] [Abstract][Full Text] [Related]
8. Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice.
Kremer A; Maurin H; Demedts D; Devijver H; Borghgraef P; Van Leuven F
J Neurosci; 2011 Dec; 31(49):18036-47. PubMed ID: 22159117
[TBL] [Abstract][Full Text] [Related]
9. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.
Fox LM; William CM; Adamowicz DH; Pitstick R; Carlson GA; Spires-Jones TL; Hyman BT
J Neuropathol Exp Neurol; 2011 Jul; 70(7):588-95. PubMed ID: 21666499
[TBL] [Abstract][Full Text] [Related]
10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
11. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
[TBL] [Abstract][Full Text] [Related]
12. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
[TBL] [Abstract][Full Text] [Related]
13. Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau.
Perreault S; Bousquet O; Lauzon M; Paiement J; Leclerc N
J Neuropathol Exp Neurol; 2009 May; 68(5):503-14. PubMed ID: 19525898
[TBL] [Abstract][Full Text] [Related]
14. MRNA Levels of ACh-Related Enzymes in the Hippocampus of THY-Tau22 Mouse: A Model of Human Tauopathy with No Signs of Motor Disturbance.
García-Gómez BE; Fernández-Gómez FJ; Muñoz-Delgado E; Buée L; Blum D; Vidal CJ
J Mol Neurosci; 2016 Apr; 58(4):411-5. PubMed ID: 26697857
[TBL] [Abstract][Full Text] [Related]
15. Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy.
Buccarello L; Grignaschi G; Castaldo AM; Di Giancamillo A; Domeneghini C; Melcangi RC; Borsello T
J Alzheimers Dis; 2017; 56(4):1279-1292. PubMed ID: 28157099
[TBL] [Abstract][Full Text] [Related]
16. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin.
Ubhi K; Rockenstein E; Doppler E; Mante M; Adame A; Patrick C; Trejo M; Crews L; Paulino A; Moessler H; Masliah E
Acta Neuropathol; 2009 Jun; 117(6):699-712. PubMed ID: 19252918
[TBL] [Abstract][Full Text] [Related]
17. Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.
Watamura N; Toba J; Yoshii A; Nikkuni M; Ohshima T
J Neurosci Res; 2016 Jan; 94(1):15-26. PubMed ID: 26400044
[TBL] [Abstract][Full Text] [Related]
18. Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease.
Belarbi K; Schindowski K; Burnouf S; Caillierez R; Grosjean ME; Demeyer D; Hamdane M; Sergeant N; Blum D; Buée L
Curr Alzheimer Res; 2009 Apr; 6(2):152-7. PubMed ID: 19355850
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.
Britschgi M; Takeda-Uchimura Y; Rockenstein E; Johns H; Masliah E; Wyss-Coray T
J Neuroinflammation; 2012 Sep; 9():220. PubMed ID: 22989354
[TBL] [Abstract][Full Text] [Related]
20. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
